# Ivermectin Nasal Drops in Post COVID-19 Parosmia

> **NCT05269030** · PHASE2 · UNKNOWN · sponsor: **Menoufia University** · enrollment: 60 (estimated)

## Conditions studied

- Parosmia

## Interventions

- **DRUG:** Ivermectin Topical
- **DRUG:** Budesonide Nasal

## Key facts

- **NCT ID:** NCT05269030
- **Lead sponsor:** Menoufia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07
- **Primary completion:** 2023-03
- **Final completion:** 2023-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05269030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05269030, "Ivermectin Nasal Drops in Post COVID-19 Parosmia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05269030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*